Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| REVLON INC /DE/REVRQ · Entity 115224 | Director · 10% owner | November 08, 2022 | November 10, 2022 |
| SIGA TECHNOLOGIES INCSIGA · Entity 6205 | Director · 10% owner | November 16, 2016 | November 18, 2016 |
| vTv Therapeutics Inc.VTVT · Entity 6614 | 10% owner | December 20, 2021 | December 21, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
REVLON INC /DE/
Report date November 08, 2022 · Filed November 10, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | IndirectOwned through wholly owned corporations | 41,676,969 |
Reported balance
After 2022-11-08 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2022-11-08 · Sale · Disposed 4,546,352 · Balance 41,676,969 F1: The shares were sold to RCH Holdings Six Inc. by Perelman Trust Company, LLC, over which MacAndrews & Forbes Incorporated ("M&F") exercises voting control, in exchange for cash consideration of $45,463.52. Mr. Perelman is the sole stockholder of M&F. The transaction was effectuated to implement certain philanthropic endeavors for Mr. Perelman. F2: Of the 41,676,969 shares of Class A Common Stock reported herein, (i) 36,470,036 shares of Class A Common Stock are owned by M&F or its wholly owned subsidiaries; and (ii) 5,206,933 shares of Class A Common Stock are owned by RCH Holdings Five Inc. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were sold to RCH Holdings Six Inc. by Perelman Trust Company, LLC, over which MacAndrews & Forbes Incorporated ("M&F") exercises voting control, in exchange for cash consideration of $45,463.52. Mr. Perelman is the sole stockholder of M&F. The transaction was effectuated to implement certain philanthropic endeavors for Mr. Perelman.
F2: Of the 41,676,969 shares of Class A Common Stock reported herein, (i) 36,470,036 shares of Class A Common Stock are owned by M&F or its wholly owned subsidiaries; and (ii) 5,206,933 shares of Class A Common Stock are owned by RCH Holdings Five Inc.
SIGA TECHNOLOGIES INC
Report date November 16, 2016 · Filed November 18, 2016
Jointly reported with MacAndrews & Forbes Inc., MacAndrews & Forbes LLC
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, Par Value $.0001 Per ShareSEC Table I · non-derivative | IndirectOwned through wholly-owned company | 24,156,358 |
Last balance in matching sequence
After 2016-11-16 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2016-11-16 · Exercise / conversion · Acquired 10,060,643 · Balance 23,591,348 F1: On October 21, 2016, SIGA Technologies, Inc. (the "Company") issued a press release announcing the commencement of a pro rata offering (the "Rights Offering") of rights to holders of the Company's common stock, par value $.0001 per share ("Common Stock"), as of the record date of October 12, 2016, to subscribe for up to an aggregate of $35,284,792 in Common Stock. Each subscription right entitled its holder to invest $0.65 towards the purchase of shares of the Company's Common Stock at a subscription price equal to the lower of $1.50 or 85% of the volume weighted average price of the Common Stock during market hours on the expiration date of the Rights Offering, conditioned on the Company obtaining sufficient proceeds from the Rights Offering and a proposed loan transaction to permit the Company to satisfy certain obligations, together with other conditions outside the control of the reporting persons (all, the "Conditions"), (continued in footnote 2) F2: (continued from footnote 1) as more fully described in the Company's prospectus relating to the Rights Offering filed with the Securities Exchange Commission on October 21, 2016. Accordingly, the reporting persons were entitled to use basic subscription rights to subscribe for up to approximately $8,781,319 in Common Stock. Furthermore, the reporting persons were also entitled to subscribe for additional shares of common stock through an oversubscription process. Upon the expiration of the Rights Offering on November 8, 2016, the subscription price was fixed at $1.50 per share of Common Stock. The Conditions were satisfied on November 16, 2016. The reporting persons exercised their basic subscription in full and oversubscription rights. Pursuant to the reporting persons' basic subscription rights, they acquired 5,854,212 shares of Common Stock. The reporting persons acquired 4,206,431 shares pursuant to their exercise of their oversubscription rights. F3: Ronald O. Perelman beneficially owns 100% of the common stock of MacAndrews & Forbes Incorporated, which in turn is the sole member of MacAndrews & Forbes LLC. Certain direct or indirect wholly-owned subsidiaries of those reporting persons hold the securities described above. Row 2 · 2016-11-16 · Grant · Acquired 565,010 · Balance 24,156,358 F4: On October 13, 2016, the Company entered into an investment agreement relating to the Rights Offering (the "Backstop Agreement"), with a direct or indirect subsidiary of the reporting persons ("Buyer") and other persons (together, the "Backstop Parties"). Under the terms of the Backstop Agreement, Buyer agreed to purchase, pursuant to a separate private placement, 79.744% of any unsubscribed shares of Common Stock offered in the Rights Offering, at the same price per share of Common Stock to be paid in the Rights Offering. The Backstop Parties, taken together, were entitled to a fee of $1.76 million for providing the backstop commitment, payable, at the option of the Company, in cash or stock or, subject to the mutual agreement of the parties, other equity securities, with Buyer entitled to 79.744% of that fee. (continued in footnote 5) F5: (continued from footnote 4) The Company delivered a total of 565,010 shares of Common Stock to Buyer in satisfaction of the fee due under the Backstop Agreement, but no other shares were acquired pursuant to the Backstop Agreement. F3: Ronald O. Perelman beneficially owns 100% of the common stock of MacAndrews & Forbes Incorporated, which in turn is the sole member of MacAndrews & Forbes LLC. Certain direct or indirect wholly-owned subsidiaries of those reporting persons hold the securities described above. |
| Subscription Rights (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.50 · Expires 2016-11-08 | IndirectOwned through wholly-owned company | 0 |
Reported balance
After 2016-11-16 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2016-11-16 · Exercise / conversion · Disposed 0 · Balance 0 F1: On October 21, 2016, SIGA Technologies, Inc. (the "Company") issued a press release announcing the commencement of a pro rata offering (the "Rights Offering") of rights to holders of the Company's common stock, par value $.0001 per share ("Common Stock"), as of the record date of October 12, 2016, to subscribe for up to an aggregate of $35,284,792 in Common Stock. Each subscription right entitled its holder to invest $0.65 towards the purchase of shares of the Company's Common Stock at a subscription price equal to the lower of $1.50 or 85% of the volume weighted average price of the Common Stock during market hours on the expiration date of the Rights Offering, conditioned on the Company obtaining sufficient proceeds from the Rights Offering and a proposed loan transaction to permit the Company to satisfy certain obligations, together with other conditions outside the control of the reporting persons (all, the "Conditions"), (continued in footnote 2) F2: (continued from footnote 1) as more fully described in the Company's prospectus relating to the Rights Offering filed with the Securities Exchange Commission on October 21, 2016. Accordingly, the reporting persons were entitled to use basic subscription rights to subscribe for up to approximately $8,781,319 in Common Stock. Furthermore, the reporting persons were also entitled to subscribe for additional shares of common stock through an oversubscription process. Upon the expiration of the Rights Offering on November 8, 2016, the subscription price was fixed at $1.50 per share of Common Stock. The Conditions were satisfied on November 16, 2016. The reporting persons exercised their basic subscription in full and oversubscription rights. Pursuant to the reporting persons' basic subscription rights, they acquired 5,854,212 shares of Common Stock. The reporting persons acquired 4,206,431 shares pursuant to their exercise of their oversubscription rights. F3: Ronald O. Perelman beneficially owns 100% of the common stock of MacAndrews & Forbes Incorporated, which in turn is the sole member of MacAndrews & Forbes LLC. Certain direct or indirect wholly-owned subsidiaries of those reporting persons hold the securities described above. |
Filing footnotes · ownership attribution and instrument terms
F1: On October 21, 2016, SIGA Technologies, Inc. (the "Company") issued a press release announcing the commencement of a pro rata offering (the "Rights Offering") of rights to holders of the Company's common stock, par value $.0001 per share ("Common Stock"), as of the record date of October 12, 2016, to subscribe for up to an aggregate of $35,284,792 in Common Stock. Each subscription right entitled its holder to invest $0.65 towards the purchase of shares of the Company's Common Stock at a subscription price equal to the lower of $1.50 or 85% of the volume weighted average price of the Common Stock during market hours on the expiration date of the Rights Offering, conditioned on the Company obtaining sufficient proceeds from the Rights Offering and a proposed loan transaction to permit the Company to satisfy certain obligations, together with other conditions outside the control of the reporting persons (all, the "Conditions"), (continued in footnote 2)
F2: (continued from footnote 1) as more fully described in the Company's prospectus relating to the Rights Offering filed with the Securities Exchange Commission on October 21, 2016. Accordingly, the reporting persons were entitled to use basic subscription rights to subscribe for up to approximately $8,781,319 in Common Stock. Furthermore, the reporting persons were also entitled to subscribe for additional shares of common stock through an oversubscription process. Upon the expiration of the Rights Offering on November 8, 2016, the subscription price was fixed at $1.50 per share of Common Stock. The Conditions were satisfied on November 16, 2016. The reporting persons exercised their basic subscription in full and oversubscription rights. Pursuant to the reporting persons' basic subscription rights, they acquired 5,854,212 shares of Common Stock. The reporting persons acquired 4,206,431 shares pursuant to their exercise of their oversubscription rights.
F3: Ronald O. Perelman beneficially owns 100% of the common stock of MacAndrews & Forbes Incorporated, which in turn is the sole member of MacAndrews & Forbes LLC. Certain direct or indirect wholly-owned subsidiaries of those reporting persons hold the securities described above.
F4: On October 13, 2016, the Company entered into an investment agreement relating to the Rights Offering (the "Backstop Agreement"), with a direct or indirect subsidiary of the reporting persons ("Buyer") and other persons (together, the "Backstop Parties"). Under the terms of the Backstop Agreement, Buyer agreed to purchase, pursuant to a separate private placement, 79.744% of any unsubscribed shares of Common Stock offered in the Rights Offering, at the same price per share of Common Stock to be paid in the Rights Offering. The Backstop Parties, taken together, were entitled to a fee of $1.76 million for providing the backstop commitment, payable, at the option of the Company, in cash or stock or, subject to the mutual agreement of the parties, other equity securities, with Buyer entitled to 79.744% of that fee. (continued in footnote 5)
F5: (continued from footnote 4) The Company delivered a total of 565,010 shares of Common Stock to Buyer in satisfaction of the fee due under the Backstop Agreement, but no other shares were acquired pursuant to the Backstop Agreement.
vTv Therapeutics Inc.
Report date December 20, 2021 · Filed December 21, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | IndirectSee footnote | 36,519,212 |
Reported balance
After 2021-12-20 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2021-12-20 · Sale · Disposed 87,000 · Balance 36,519,212 F1: The ROP Revocable Trust dated 1/9/2018 (the "ROP Revocable Trust"), of which Mr. Ronald O. Perelman is the sole trustee and sole beneficiary, is the sole stockholder of MacAndrews & Forbes Incorporated ("M&F Inc."), which is the parent of MFV Holdings One LLC ("MFV") and MacAndrews & Forbes LLC ("M&F LLC"), which is the parent of MacAndrews & Forbes Group LLC ("M&F Group"). The ROP Revocable Trust is also the sole stockholder of Thirty Six East Corporation ("Thirty Six East"). M&F Group, MFV and Thirty Six East hold the securities described above. (cont'd on FN 2) F2: (cont'd from FN 1) Mr. Perelman, the ROP Revocable Trust, M&F Inc., M&F LLC, M&F Group, MFV and Thirty Six East may be deemed to be directors by deputization of vTv Therapeutics Inc. (the "Issuer") by virtue of the role of Rich Nelson, director of the Issuer, as Executive Vice President Corporate and Business Development of Vericast and certain rights of M&F TTP Holdings Two LLC, an indirect subsidiary of M&F Inc. ("M&F TTP"), pursuant to the Investor Rights Agreement, dated as of July 29, 2015, between the Issuer and M&F TTP, as successor in interest to vTv Therapeutics Holdings LLC. |
Filing footnotes · ownership attribution and instrument terms
F1: The ROP Revocable Trust dated 1/9/2018 (the "ROP Revocable Trust"), of which Mr. Ronald O. Perelman is the sole trustee and sole beneficiary, is the sole stockholder of MacAndrews & Forbes Incorporated ("M&F Inc."), which is the parent of MFV Holdings One LLC ("MFV") and MacAndrews & Forbes LLC ("M&F LLC"), which is the parent of MacAndrews & Forbes Group LLC ("M&F Group"). The ROP Revocable Trust is also the sole stockholder of Thirty Six East Corporation ("Thirty Six East"). M&F Group, MFV and Thirty Six East hold the securities described above. (cont'd on FN 2)
F2: (cont'd from FN 1) Mr. Perelman, the ROP Revocable Trust, M&F Inc., M&F LLC, M&F Group, MFV and Thirty Six East may be deemed to be directors by deputization of vTv Therapeutics Inc. (the "Issuer") by virtue of the role of Rich Nelson, director of the Issuer, as Executive Vice President Corporate and Business Development of Vericast and certain rights of M&F TTP Holdings Two LLC, an indirect subsidiary of M&F Inc. ("M&F TTP"), pursuant to the Investor Rights Agreement, dated as of July 29, 2015, between the Issuer and M&F TTP, as successor in interest to vTv Therapeutics Holdings LLC.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Light & Wonder, Inc.
Report date October 12, 2020 · Filed October 13, 2020
Section 16 reporting ended · disclosed 2020-10-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 8,871,313 |
Reported balance
After 2020-10-12 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2020-10-12 · Sale · Disposed 1,964,285 · Balance 8,871,313 F1: Mr. Perelman is the sole beneficiary and trustee of The ROP Revocable Trust dated 1/9/2018 (the "Trust"), which directly holds 122,728 shares of Common Stock. The Trust is also the sole stockholder of MacAndrews & Forbes Incorporated, which is the sole stockholder, directly or indirectly, of each of SGMS Acquisition Corporation, RLX Holdings Two LLC, SGMS Acquisition Two LLC, SGMS Acquisition Three LLC and MacAndrews & Forbes Group, LLC, which hold the remaining securities described above. Mr. Perelman does not own any shares of Common Stock directly. On October 12, 2020, SGMS Acquisition Corporation, RLX Holdings Two LLC, SGMS Acquisition Two LLC and SGMS Acquisition Three LLC sold an aggregate of 1,964,285 shares of Common Stock pursuant to the previously disclosed Stock Purchase Agreement by and among SGMS Acquisition Corporation, RLX Holdings Two LLC, SGMS Acquisition Two LLC, SGMS Acquisition Three LLC, MacAndrews & Forbes Group, LLC and Pivot Buyer LLC. |
Filing footnotes · ownership attribution and instrument terms
F1: Mr. Perelman is the sole beneficiary and trustee of The ROP Revocable Trust dated 1/9/2018 (the "Trust"), which directly holds 122,728 shares of Common Stock. The Trust is also the sole stockholder of MacAndrews & Forbes Incorporated, which is the sole stockholder, directly or indirectly, of each of SGMS Acquisition Corporation, RLX Holdings Two LLC, SGMS Acquisition Two LLC, SGMS Acquisition Three LLC and MacAndrews & Forbes Group, LLC, which hold the remaining securities described above. Mr. Perelman does not own any shares of Common Stock directly. On October 12, 2020, SGMS Acquisition Corporation, RLX Holdings Two LLC, SGMS Acquisition Two LLC and SGMS Acquisition Three LLC sold an aggregate of 1,964,285 shares of Common Stock pursuant to the previously disclosed Stock Purchase Agreement by and among SGMS Acquisition Corporation, RLX Holdings Two LLC, SGMS Acquisition Two LLC, SGMS Acquisition Three LLC, MacAndrews & Forbes Group, LLC and Pivot Buyer LLC.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 27, 2019 Filed Sep 27, 2019 16:31 UTC | vTv Therapeutics Inc. VTVT · Entity 6614 | PurchaseClass A common stock | 1,369,863 | $1.46 | $1,999,999.98 |
DisclosureSEC source: 0001140361-19-017447 · form4.xml · nonDerivative · entry 1 PERELMAN RONALD O · CIK 0001186472 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 24,876,760 F1 · ownership.nature: The ROP Revocable Trust dated 1/9/2018 (the "ROP Revocable Trust"), of which Mr. Ronald O. Perelman is the sole trustee and sole beneficiary, is the sole stockholder of MacAndrews & Forbes Incorporated ("M&F Inc."), which is the parent of MFV Holdings One LLC ("MFV") and MacAndrews & Forbes LLC ("M&F LLC"), which is the parent of M&F Group. M&F Group and MFV hold the securities described above. Mr. Perelman, the ROP Revocable Trust, M&F Inc., M&F LLC, M&F Group and MFV may be deemed to be directors by deputization of vTv Therapeutics Inc. (the "Issuer") by virtue of their relationship with Steven M. Cohen and Paul G. Savas, directors of the Issuer, and certain rights of M&F TTP Holdings Two LLC, an indirect subsidiary of M&F Inc. ("M&F TTP"), pursuant to the Investor Rights Agreement, dated as of July 29, 2015, between the Issuer and M&F TTP, as successor in interest to vTv Therapeutics Holdings LLC. Read SEC document |
| September 26, 2019 Filed Sep 27, 2019 16:31 UTC | vTv Therapeutics Inc. VTVT · Entity 6614 | OtherCommon Stock Purchase Warrant · Derivative | 1 | Not disclosed Strike: $1.68 | Not disclosed |
DisclosureSEC source: 0001140361-19-017447 · form4.xml · derivative · entry 3 PERELMAN RONALD O · CIK 0001186472 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1 Underlying: Class A common stock · 400,990 shares Expires 2026-09-26 F3 · kind: In consideration for the commitment of M&F Group under the Letter Agreement, the Issuer issued M&F Group a warrant (the "Warrant") to purchase 400,990 shares of Common Stock, exercisable at a price of $1.68, which is 115% of the option price under the Letter Agreement. The Warrant is exercisable until September 26, 2026. F3 · price: In consideration for the commitment of M&F Group under the Letter Agreement, the Issuer issued M&F Group a warrant (the "Warrant") to purchase 400,990 shares of Common Stock, exercisable at a price of $1.68, which is 115% of the option price under the Letter Agreement. The Warrant is exercisable until September 26, 2026. F3 · balance_after: In consideration for the commitment of M&F Group under the Letter Agreement, the Issuer issued M&F Group a warrant (the "Warrant") to purchase 400,990 shares of Common Stock, exercisable at a price of $1.68, which is 115% of the option price under the Letter Agreement. The Warrant is exercisable until September 26, 2026. F1 · ownership.nature: The ROP Revocable Trust dated 1/9/2018 (the "ROP Revocable Trust"), of which Mr. Ronald O. Perelman is the sole trustee and sole beneficiary, is the sole stockholder of MacAndrews & Forbes Incorporated ("M&F Inc."), which is the parent of MFV Holdings One LLC ("MFV") and MacAndrews & Forbes LLC ("M&F LLC"), which is the parent of M&F Group. M&F Group and MFV hold the securities described above. Mr. Perelman, the ROP Revocable Trust, M&F Inc., M&F LLC, M&F Group and MFV may be deemed to be directors by deputization of vTv Therapeutics Inc. (the "Issuer") by virtue of their relationship with Steven M. Cohen and Paul G. Savas, directors of the Issuer, and certain rights of M&F TTP Holdings Two LLC, an indirect subsidiary of M&F Inc. ("M&F TTP"), pursuant to the Investor Rights Agreement, dated as of July 29, 2015, between the Issuer and M&F TTP, as successor in interest to vTv Therapeutics Holdings LLC. Read SEC document |
| September 26, 2019 Filed Sep 27, 2019 16:31 UTC | vTv Therapeutics Inc. VTVT · Entity 6614 | OtherCall Option (right to buy) · Derivative | 1 | Not disclosed Strike: $1.46 | Not disclosed |
DisclosureSEC source: 0001140361-19-017447 · form4.xml · derivative · entry 2 PERELMAN RONALD O · CIK 0001186472 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1 Underlying: Class A common stock · 6,849,315 shares Expires 2020-09-26 F2 · kind: On September 26, 2019, M&F Group entered into a letter agreement (the "Letter Agreement"), with the Issuer for M&F Group's commitment to purchase, at the Issuer's option, exercisable on demand during a one-year period (the "Investment Period"), the Company's Class A common stock, par value $0.01 per share ("Common Stock"), at a per share price of $1.46. The Letter Agreement also permits M&F Group to exercise an option to purchase Common Stock at the same price up to three times during the Investment Period. The aggregate amount of Common Stock that may be purchased by M&F Group is limited to $10.0 million. On September 27, 2019, the Issuer exercised its right to have M&F Group purchase 1,369,863 shares of Common Stock for a total purchase price of $2,000,000 in cash. F2 · price: On September 26, 2019, M&F Group entered into a letter agreement (the "Letter Agreement"), with the Issuer for M&F Group's commitment to purchase, at the Issuer's option, exercisable on demand during a one-year period (the "Investment Period"), the Company's Class A common stock, par value $0.01 per share ("Common Stock"), at a per share price of $1.46. The Letter Agreement also permits M&F Group to exercise an option to purchase Common Stock at the same price up to three times during the Investment Period. The aggregate amount of Common Stock that may be purchased by M&F Group is limited to $10.0 million. On September 27, 2019, the Issuer exercised its right to have M&F Group purchase 1,369,863 shares of Common Stock for a total purchase price of $2,000,000 in cash. F2 · balance_after: On September 26, 2019, M&F Group entered into a letter agreement (the "Letter Agreement"), with the Issuer for M&F Group's commitment to purchase, at the Issuer's option, exercisable on demand during a one-year period (the "Investment Period"), the Company's Class A common stock, par value $0.01 per share ("Common Stock"), at a per share price of $1.46. The Letter Agreement also permits M&F Group to exercise an option to purchase Common Stock at the same price up to three times during the Investment Period. The aggregate amount of Common Stock that may be purchased by M&F Group is limited to $10.0 million. On September 27, 2019, the Issuer exercised its right to have M&F Group purchase 1,369,863 shares of Common Stock for a total purchase price of $2,000,000 in cash. F1 · ownership.nature: The ROP Revocable Trust dated 1/9/2018 (the "ROP Revocable Trust"), of which Mr. Ronald O. Perelman is the sole trustee and sole beneficiary, is the sole stockholder of MacAndrews & Forbes Incorporated ("M&F Inc."), which is the parent of MFV Holdings One LLC ("MFV") and MacAndrews & Forbes LLC ("M&F LLC"), which is the parent of M&F Group. M&F Group and MFV hold the securities described above. Mr. Perelman, the ROP Revocable Trust, M&F Inc., M&F LLC, M&F Group and MFV may be deemed to be directors by deputization of vTv Therapeutics Inc. (the "Issuer") by virtue of their relationship with Steven M. Cohen and Paul G. Savas, directors of the Issuer, and certain rights of M&F TTP Holdings Two LLC, an indirect subsidiary of M&F Inc. ("M&F TTP"), pursuant to the Investor Rights Agreement, dated as of July 29, 2015, between the Issuer and M&F TTP, as successor in interest to vTv Therapeutics Holdings LLC. Read SEC document |
| September 20, 2019 Filed Sep 23, 2019 21:01 UTC | Light & Wonder, Inc. SGMS · Entity 9758 | PurchaseCommon Stock | 100,000 | $22.98 | $2,298,000.00 |
DisclosureSEC source: 0000950157-19-001057 · form4.xml · nonDerivative · entry 1 PERELMAN RONALD O · CIK 0001186472 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 36,643,768 F1 · price: The transaction was executed in multiple trades at prices ranging from $22.55 to $23.15. The price reported above reflects the weighted average purchase price. Details regarding aggregated purchase transactions will be provided upon request by the Commission staff, the issuer or a security holder of the issuer. F2 · ownership.nature: Mr. Perelman is the sole beneficiary and trustee of The ROP Revocable Trust dated 1/9/2018 (the "Trust"), which directly holds 88,032 shares of common stock. The Trust is also the sole stockholder of MacAndrews & Forbes Incorporated, which is the sole stockholder, directly or indirectly, of each of SGMS Acquisition Corporation, RLX Holdings Two LLC, SGMS Acquisition Two LLC, SGMS Acquisition Three LLC and MacAndrews & Forbes Group, LLC, which hold the remaining securities described above. Read SEC document |
| September 18, 2019 Filed Sep 19, 2019 00:34 UTC | Light & Wonder, Inc. SGMS · Entity 9758 | PurchaseCommon Stock | 100,000 | $22.41 | $2,241,000.00 |
DisclosureSEC source: 0000950157-19-001047 · form4.xml · nonDerivative · entry 1 PERELMAN RONALD O · CIK 0001186472 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 36,543,768 F1 · price: The transaction was executed in multiple trades at prices ranging from $21.83 to $22.62. The price reported above reflects the weighted average purchase price. Details regarding aggregated purchase transactions will be provided upon request by the Commission staff, the issuer or a security holder of the issuer. F2 · ownership.nature: Mr. Perelman is the sole beneficiary and trustee of The ROP Revocable Trust dated 1/9/2018 (the "Trust"), which directly holds 88,032 shares of common stock. The Trust is also the sole stockholder of MacAndrews & Forbes Incorporated, which is the sole stockholder, directly or indirectly, of each of SGMS Acquisition Corporation, RLX Holdings Two LLC, SGMS Acquisition Two LLC, SGMS Acquisition Three LLC and MacAndrews & Forbes Group, LLC, which hold the remaining securities described above. Read SEC document |
| September 18, 2019 Filed Sep 18, 2019 16:40 UTC | vTv Therapeutics Inc. VTVT · Entity 6614 | OtherCall Option (right to buy) · Derivative | 1 | $0.00 Strike: $1.65 | $0.00 |
DisclosureSEC source: 0001140361-19-016918 · form4.xml · derivative · entry 2 PERELMAN RONALD O · CIK 0001186472 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1 Underlying: Class A common stock · 606,061 shares Expires 2020-03-18 F2 · kind: On March 18, 2019, M&F Group entered into a letter agreement (the "Letter Agreement"), with the Issuer for M&F Group's commitment to purchase, at the Issuer's option, exercisable on demand during a one-year period (the "Investment Period"), the Company's Class A common stock, par value $0.01 per share ("Common Stock") at a per share price of $1.65. The Letter Agreement also permits M&F Group to exercise an option to purchase Common Stock at the same price up to three times during the Investment Period. The aggregate amount of Common Stock that may be purchased by M&F Group is limited to $9.0 million. On September 18, 2019, the Issuer exercised its right to have M&F Group purchase 606,061 shares of Common Stock for a total purchase price of $1,000,000 in cash. F2 · balance_after: On March 18, 2019, M&F Group entered into a letter agreement (the "Letter Agreement"), with the Issuer for M&F Group's commitment to purchase, at the Issuer's option, exercisable on demand during a one-year period (the "Investment Period"), the Company's Class A common stock, par value $0.01 per share ("Common Stock") at a per share price of $1.65. The Letter Agreement also permits M&F Group to exercise an option to purchase Common Stock at the same price up to three times during the Investment Period. The aggregate amount of Common Stock that may be purchased by M&F Group is limited to $9.0 million. On September 18, 2019, the Issuer exercised its right to have M&F Group purchase 606,061 shares of Common Stock for a total purchase price of $1,000,000 in cash. F1 · ownership.nature: The ROP Revocable Trust dated 1/9/2018 (the "ROP Revocable Trust"), of which Mr. Ronald O. Perelman is the sole trustee and sole beneficiary, is the sole stockholder of MacAndrews & Forbes Incorporated ("M&F Inc."), which is the parent of MFV Holdings One LLC ("MFV") and MacAndrews & Forbes LLC ("M&F LLC"), which is the parent of M&F Group. M&F Group and MFV hold the securities described above. Mr. Perelman, the ROP Revocable Trust, M&F Inc., M&F LLC, M&F Group and MFV may be deemed to be directors by deputization of vTv Therapeutics Inc. (the "Issuer") by virtue of their relationship with Steven M. Cohen and Paul G. Savas, directors of the Issuer, and certain rights of M&F TTP Holdings Two LLC, an indirect subsidiary of M&F Inc. ("M&F TTP"), pursuant to the Investor Rights Agreement, dated as of July 29, 2015, between the Issuer and M&F TTP, as successor in interest to vTv Therapeutics Holdings LLC. Read SEC document |
| September 18, 2019 Filed Sep 18, 2019 16:40 UTC | vTv Therapeutics Inc. VTVT · Entity 6614 | PurchaseClass A common stock | 606,061 | $1.65 | $1,000,000.65 |
DisclosureSEC source: 0001140361-19-016918 · form4.xml · nonDerivative · entry 1 PERELMAN RONALD O · CIK 0001186472 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 23,506,897 F1 · ownership.nature: The ROP Revocable Trust dated 1/9/2018 (the "ROP Revocable Trust"), of which Mr. Ronald O. Perelman is the sole trustee and sole beneficiary, is the sole stockholder of MacAndrews & Forbes Incorporated ("M&F Inc."), which is the parent of MFV Holdings One LLC ("MFV") and MacAndrews & Forbes LLC ("M&F LLC"), which is the parent of M&F Group. M&F Group and MFV hold the securities described above. Mr. Perelman, the ROP Revocable Trust, M&F Inc., M&F LLC, M&F Group and MFV may be deemed to be directors by deputization of vTv Therapeutics Inc. (the "Issuer") by virtue of their relationship with Steven M. Cohen and Paul G. Savas, directors of the Issuer, and certain rights of M&F TTP Holdings Two LLC, an indirect subsidiary of M&F Inc. ("M&F TTP"), pursuant to the Investor Rights Agreement, dated as of July 29, 2015, between the Issuer and M&F TTP, as successor in interest to vTv Therapeutics Holdings LLC. Read SEC document |
| September 11, 2019 Filed Sep 11, 2019 16:42 UTC | vTv Therapeutics Inc. VTVT · Entity 6614 | OtherCall Option (right to buy) · Derivative | 1 | $0.00 Strike: $1.65 | $0.00 |
DisclosureSEC source: 0001140361-19-016526 · form4.xml · derivative · entry 2 PERELMAN RONALD O · CIK 0001186472 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1 Underlying: Class A common stock · 606,061 shares Expires 2020-03-18 F2 · kind: On March 18, 2019, M&F Group entered into a letter agreement (the "Letter Agreement"), with the Issuer for M&F Group's commitment to purchase, at the Issuer's option, exercisable on demand during a one-year period (the "Investment Period"), the Company's Class A common stock, par value $0.01 per share ("Common Stock") at a per share price of $1.65. The Letter Agreement also permits M&F Group to exercise an option to purchase Common Stock at the same price up to three times during the Investment Period. The aggregate amount of Common Stock that may be purchased by M&F Group is limited to $9.0 million. On September 11, 2019, the Issuer exercised its right to have M&F Group purchase 606,061 shares of Common Stock for a total purchase price of $1,000,000 in cash. F2 · balance_after: On March 18, 2019, M&F Group entered into a letter agreement (the "Letter Agreement"), with the Issuer for M&F Group's commitment to purchase, at the Issuer's option, exercisable on demand during a one-year period (the "Investment Period"), the Company's Class A common stock, par value $0.01 per share ("Common Stock") at a per share price of $1.65. The Letter Agreement also permits M&F Group to exercise an option to purchase Common Stock at the same price up to three times during the Investment Period. The aggregate amount of Common Stock that may be purchased by M&F Group is limited to $9.0 million. On September 11, 2019, the Issuer exercised its right to have M&F Group purchase 606,061 shares of Common Stock for a total purchase price of $1,000,000 in cash. F1 · ownership.nature: The ROP Revocable Trust dated 1/9/2018 (the "ROP Revocable Trust"), of which Mr. Ronald O. Perelman is the sole trustee and sole beneficiary, is the sole stockholder of MacAndrews & Forbes Incorporated ("M&F Inc."), which is the parent of MFV Holdings One LLC ("MFV") and MacAndrews & Forbes LLC ("M&F LLC"), which is the parent of M&F Group. M&F Group and MFV hold the securities described above. Mr. Perelman, the ROP Revocable Trust, M&F Inc., M&F LLC, M&F Group and MFV may be deemed to be directors by deputization of vTv Therapeutics Inc. (the "Issuer") by virtue of their relationship with Steven M. Cohen and Paul G. Savas, directors of the Issuer, and certain rights of M&F TTP Holdings Two LLC, an indirect subsidiary of M&F Inc. ("M&F TTP"), pursuant to the Investor Rights Agreement, dated as of July 29, 2015, between the Issuer and M&F TTP, as successor in interest to vTv Therapeutics Holdings LLC. Read SEC document |
| September 11, 2019 Filed Sep 11, 2019 16:42 UTC | vTv Therapeutics Inc. VTVT · Entity 6614 | PurchaseClass A common stock | 606,061 | $1.65 | $1,000,000.65 |
DisclosureSEC source: 0001140361-19-016526 · form4.xml · nonDerivative · entry 1 PERELMAN RONALD O · CIK 0001186472 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 22,900,836 F1 · ownership.nature: The ROP Revocable Trust dated 1/9/2018 (the "ROP Revocable Trust"), of which Mr. Ronald O. Perelman is the sole trustee and sole beneficiary, is the sole stockholder of MacAndrews & Forbes Incorporated ("M&F Inc."), which is the parent of MFV Holdings One LLC ("MFV") and MacAndrews & Forbes LLC ("M&F LLC"), which is the parent of M&F Group. M&F Group and MFV hold the securities described above. Mr. Perelman, the ROP Revocable Trust, M&F Inc., M&F LLC, M&F Group and MFV may be deemed to be directors by deputization of vTv Therapeutics Inc. (the "Issuer") by virtue of their relationship with Steven M. Cohen and Paul G. Savas, directors of the Issuer, and certain rights of M&F TTP Holdings Two LLC, an indirect subsidiary of M&F Inc. ("M&F TTP"), pursuant to the Investor Rights Agreement, dated as of July 29, 2015, between the Issuer and M&F TTP, as successor in interest to vTv Therapeutics Holdings LLC. Read SEC document |
| September 04, 2019 Filed Sep 4, 2019 18:24 UTC | vTv Therapeutics Inc. VTVT · Entity 6614 | OtherCall Option (right to buy) · Derivative | 1 | $0.00 Strike: $1.65 | $0.00 |
DisclosureSEC source: 0001140361-19-016100 · form4.xml · derivative · entry 2 PERELMAN RONALD O · CIK 0001186472 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1 Underlying: Class A common stock · 606,061 shares Expires 2020-03-18 F2 · kind: On March 18, 2019, M&F Group entered into a letter agreement (the "Letter Agreement"), with the Issuer for M&F Group's commitment to purchase, at the Issuer's option, exercisable on demand during a one-year period (the "Investment Period"), the Company's Class A common stock, par value $0.01 per share ("Common Stock") at a per share price of $1.65. The Letter Agreement also permits M&F Group to exercise an option to purchase Common Stock at the same price up to three times during the Investment Period. The aggregate amount of Common Stock that may be purchased by M&F Group is limited to $9.0 million. On September 4, 2019, the Issuer exercised its right to have M&F Group purchase 606,061 shares of Common Stock for a total purchase price of $1,000,000 in cash. F2 · balance_after: On March 18, 2019, M&F Group entered into a letter agreement (the "Letter Agreement"), with the Issuer for M&F Group's commitment to purchase, at the Issuer's option, exercisable on demand during a one-year period (the "Investment Period"), the Company's Class A common stock, par value $0.01 per share ("Common Stock") at a per share price of $1.65. The Letter Agreement also permits M&F Group to exercise an option to purchase Common Stock at the same price up to three times during the Investment Period. The aggregate amount of Common Stock that may be purchased by M&F Group is limited to $9.0 million. On September 4, 2019, the Issuer exercised its right to have M&F Group purchase 606,061 shares of Common Stock for a total purchase price of $1,000,000 in cash. F1 · ownership.nature: The ROP Revocable Trust dated 1/9/2018 (the "ROP Revocable Trust"), of which Mr. Ronald O. Perelman is the sole trustee and sole beneficiary, is the sole stockholder of MacAndrews & Forbes Incorporated ("M&F Inc."), which is the parent of MFV Holdings One LLC ("MFV") and MacAndrews & Forbes LLC ("M&F LLC"), which is the parent of M&F Group. M&F Group and MFV hold the securities described above. Mr. Perelman, the ROP Revocable Trust, M&F Inc., M&F LLC, M&F Group and MFV may be deemed to be directors by deputization of vTv Therapeutics Inc. (the "Issuer") by virtue of their relationship with Steven M. Cohen and Paul G. Savas, directors of the Issuer, and certain rights of M&F TTP Holdings Two LLC, an indirect subsidiary of M&F Inc. ("M&F TTP"), pursuant to the Investor Rights Agreement, dated as of July 29, 2015, between the Issuer and M&F TTP, as successor in interest to vTv Therapeutics Holdings LLC. Read SEC document |
| September 04, 2019 Filed Sep 4, 2019 18:24 UTC | vTv Therapeutics Inc. VTVT · Entity 6614 | PurchaseClass A common stock | 606,061 | $1.65 | $1,000,000.65 |
DisclosureSEC source: 0001140361-19-016100 · form4.xml · nonDerivative · entry 1 PERELMAN RONALD O · CIK 0001186472 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 22,294,775 F1 · ownership.nature: The ROP Revocable Trust dated 1/9/2018 (the "ROP Revocable Trust"), of which Mr. Ronald O. Perelman is the sole trustee and sole beneficiary, is the sole stockholder of MacAndrews & Forbes Incorporated ("M&F Inc."), which is the parent of MFV Holdings One LLC ("MFV") and MacAndrews & Forbes LLC ("M&F LLC"), which is the parent of M&F Group. M&F Group and MFV hold the securities described above. Mr. Perelman, the ROP Revocable Trust, M&F Inc., M&F LLC, M&F Group and MFV may be deemed to be directors by deputization of vTv Therapeutics Inc. (the "Issuer") by virtue of their relationship with Steven M. Cohen and Paul G. Savas, directors of the Issuer, and certain rights of M&F TTP Holdings Two LLC, an indirect subsidiary of M&F Inc. ("M&F TTP"), pursuant to the Investor Rights Agreement, dated as of July 29, 2015, between the Issuer and M&F TTP, as successor in interest to vTv Therapeutics Holdings LLC. Read SEC document |
| August 22, 2019 Filed Aug 22, 2019 18:37 UTC | vTv Therapeutics Inc. VTVT · Entity 6614 | PurchaseClass A common stock | 50,000 | $1.38 | $69,000.00 |
DisclosureSEC source: 0001140361-19-015481 · form4.xml · nonDerivative · entry 1 PERELMAN RONALD O · CIK 0001186472 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 21,688,714 F1 · price: The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $1.365 to $1.40, inclusive. The reporting person undertakes to provide to vTv Therapeutics Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the range set forth in this footnote to this Form 4. F2 · ownership.nature: The ROP Revocable Trust dated 1/9/2018 (the "ROP Revocable Trust"), of which Mr. Ronald O. Perelman is the sole trustee and sole beneficiary, is the sole stockholder of MacAndrews & Forbes Incorporated ("M&F Inc."), which is the parent of MFV Holdings One LLC ("MFV") and MacAndrews & Forbes LLC ("M&F LLC"), which is the parent of M&F Group. M&F Group and MFV hold the securities described above. Mr. Perelman, the ROP Revocable Trust, M&F Inc., M&F LLC, M&F Group and MFV may be deemed to be directors by deputization of vTv Therapeutics Inc. (the "Issuer") by virtue of their relationship with Steven M. Cohen and Paul G. Savas, directors of the Issuer, and certain rights of M&F TTP Holdings Two LLC, an indirect subsidiary of M&F Inc. ("M&F TTP"), pursuant to the Investor Rights Agreement, dated as of July 29, 2015, between the Issuer and M&F TTP, as successor in interest to vTv Therapeutics Holdings LLC. Read SEC document |
| August 19, 2019 Filed Aug 19, 2019 19:38 UTC | vTv Therapeutics Inc. VTVT · Entity 6614 | PurchaseClass A common stock | 150,000 | $1.31 | $195,900.00 |
DisclosureSEC source: 0001140361-19-015323 · form4.xml · nonDerivative · entry 1 PERELMAN RONALD O · CIK 0001186472 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 21,638,714 F1 · price: The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $1.275 to $1.32, inclusive. The reporting person undertakes to provide to vTv Therapeutics Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the range set forth in this footnote to this Form 4. F2 · ownership.nature: The ROP Revocable Trust dated 1/9/2018 (the "ROP Revocable Trust"), of which Mr. Ronald O. Perelman is the sole trustee and sole beneficiary, is the sole stockholder of MacAndrews & Forbes Incorporated ("M&F Inc."), which is the parent of MFV Holdings One LLC ("MFV") and MacAndrews & Forbes LLC ("M&F LLC"), which is the parent of M&F Group. M&F Group and MFV hold the securities described above. Mr. Perelman, the ROP Revocable Trust, M&F Inc., M&F LLC, M&F Group and MFV may be deemed to be directors by deputization of vTv Therapeutics Inc. (the "Issuer") by virtue of their relationship with Steven M. Cohen and Paul G. Savas, directors of the Issuer, and certain rights of M&F TTP Holdings Two LLC, an indirect subsidiary of M&F Inc. ("M&F TTP"), pursuant to the Investor Rights Agreement, dated as of July 29, 2015, between the Issuer and M&F TTP, as successor in interest to vTv Therapeutics Holdings LLC. Read SEC document |
| August 06, 2019 Filed Aug 6, 2019 16:40 UTC | vTv Therapeutics Inc. VTVT · Entity 6614 | OtherCall Option (right to buy) · Derivative | 1 | $0.00 Strike: $1.65 | $0.00 |
DisclosureSEC source: 0001140361-19-014349 · form4.xml · derivative · entry 2 PERELMAN RONALD O · CIK 0001186472 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1 Underlying: Class A common stock · 1,212,121 shares Expires 2020-03-18 F2 · kind: On March 18, 2019, M&F Group entered into a letter agreement (the "Letter Agreement"), with the Issuer for M&F Group's commitment to purchase, at the Issuer's option, exercisable on demand during a one-year period (the "Investment Period"), the Company's Class A common stock, par value $0.01 per share ("Common Stock") at a per share price of $1.65. The Letter Agreement also permits M&F Group to exercise an option to purchase Common Stock at the same price up to three times during the Investment Period. The aggregate amount of Common Stock that may be purchased by M&F Group is limited to $9.0 million. On August 6, 2019, the Issuer exercised its right to have M&F Group purchase 1,212,121 shares of Common Stock for a total purchase price of $2,000,000 in cash. F2 · balance_after: On March 18, 2019, M&F Group entered into a letter agreement (the "Letter Agreement"), with the Issuer for M&F Group's commitment to purchase, at the Issuer's option, exercisable on demand during a one-year period (the "Investment Period"), the Company's Class A common stock, par value $0.01 per share ("Common Stock") at a per share price of $1.65. The Letter Agreement also permits M&F Group to exercise an option to purchase Common Stock at the same price up to three times during the Investment Period. The aggregate amount of Common Stock that may be purchased by M&F Group is limited to $9.0 million. On August 6, 2019, the Issuer exercised its right to have M&F Group purchase 1,212,121 shares of Common Stock for a total purchase price of $2,000,000 in cash. F1 · ownership.nature: The ROP Revocable Trust dated 1/9/2018 (the "ROP Revocable Trust"), of which Mr. Ronald O. Perelman is the sole trustee and sole beneficiary, is the sole stockholder of MacAndrews & Forbes Incorporated ("M&F Inc."), which is the parent of MFV Holdings One LLC ("MFV") and MacAndrews & Forbes LLC ("M&F LLC"), which is the parent of M&F Group. M&F Group and MFV hold the securities described above. Mr. Perelman, the ROP Revocable Trust, M&F Inc., M&F LLC, M&F Group and MFV may be deemed to be directors by deputization of vTv Therapeutics Inc. (the "Issuer") by virtue of their relationship with Steven M. Cohen and Paul G. Savas, directors of the Issuer, and certain rights of M&F TTP Holdings Two LLC, an indirect subsidiary of M&F Inc. ("M&F TTP"), pursuant to the Investor Rights Agreement, dated as of July 29, 2015, between the Issuer and M&F TTP, as successor in interest to vTv Therapeutics Holdings LLC. Read SEC document |
| August 06, 2019 Filed Aug 6, 2019 16:40 UTC | vTv Therapeutics Inc. VTVT · Entity 6614 | PurchaseClass A common stock | 1,212,121 | $1.65 | $1,999,999.65 |
DisclosureSEC source: 0001140361-19-014349 · form4.xml · nonDerivative · entry 1 PERELMAN RONALD O · CIK 0001186472 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 21,488,714 F1 · ownership.nature: The ROP Revocable Trust dated 1/9/2018 (the "ROP Revocable Trust"), of which Mr. Ronald O. Perelman is the sole trustee and sole beneficiary, is the sole stockholder of MacAndrews & Forbes Incorporated ("M&F Inc."), which is the parent of MFV Holdings One LLC ("MFV") and MacAndrews & Forbes LLC ("M&F LLC"), which is the parent of M&F Group. M&F Group and MFV hold the securities described above. Mr. Perelman, the ROP Revocable Trust, M&F Inc., M&F LLC, M&F Group and MFV may be deemed to be directors by deputization of vTv Therapeutics Inc. (the "Issuer") by virtue of their relationship with Steven M. Cohen and Paul G. Savas, directors of the Issuer, and certain rights of M&F TTP Holdings Two LLC, an indirect subsidiary of M&F Inc. ("M&F TTP"), pursuant to the Investor Rights Agreement, dated as of July 29, 2015, between the Issuer and M&F TTP, as successor in interest to vTv Therapeutics Holdings LLC. Read SEC document |
| July 09, 2019 Filed Jul 9, 2019 16:35 UTC | vTv Therapeutics Inc. VTVT · Entity 6614 | OtherCall Option (right to buy) · Derivative | 1 | $0.00 Strike: $1.65 | $0.00 |
DisclosureSEC source: 0001140361-19-012655 · form4.xml · derivative · entry 2 PERELMAN RONALD O · CIK 0001186472 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1 Underlying: Class A common stock · 1,212,121 shares Expires 2020-03-18 F2 · kind: On March 18, 2019, M&F Group entered into a letter agreement (the "Letter Agreement"), with the Issuer for M&F Group's commitment to purchase, at the Issuer's option, exercisable on demand during a one-year period (the "Investment Period"), the Company's Class A common stock, par value $0.01 per share ("Common Stock") at a per share price of $1.65. The Letter Agreement also permits M&F Group to exercise an option to purchase Common Stock at the same price up to three times during the Investment Period. The aggregate amount of Common Stock that may be purchased by M&F Group is limited to $9.0 million. On July 9, 2019, the Issuer exercised its right to have M&F Group purchase 1,212,121 shares of Common Stock for a total purchase price of $2,000,000 in cash. F2 · balance_after: On March 18, 2019, M&F Group entered into a letter agreement (the "Letter Agreement"), with the Issuer for M&F Group's commitment to purchase, at the Issuer's option, exercisable on demand during a one-year period (the "Investment Period"), the Company's Class A common stock, par value $0.01 per share ("Common Stock") at a per share price of $1.65. The Letter Agreement also permits M&F Group to exercise an option to purchase Common Stock at the same price up to three times during the Investment Period. The aggregate amount of Common Stock that may be purchased by M&F Group is limited to $9.0 million. On July 9, 2019, the Issuer exercised its right to have M&F Group purchase 1,212,121 shares of Common Stock for a total purchase price of $2,000,000 in cash. F1 · ownership.nature: The ROP Revocable Trust dated 1/9/2018 (the "ROP Revocable Trust"), of which Mr. Ronald O. Perelman is the sole trustee and sole beneficiary, is the sole stockholder of MacAndrews & Forbes Incorporated ("M&F Inc."), which is the parent of MFV Holdings One LLC ("MFV") and MacAndrews & Forbes LLC ("M&F LLC"), which is the parent of M&F Group. M&F Group and MFV hold the securities described above. Mr. Perelman, the ROP Revocable Trust, M&F Inc., M&F LLC, M&F Group and MFV may be deemed to be directors by deputization of vTv Therapeutics Inc. (the "Issuer") by virtue of their relationship with Steven M. Cohen and Paul G. Savas, directors of the Issuer, and certain rights of M&F TTP Holdings Two LLC, an indirect subsidiary of M&F Inc. ("M&F TTP"), pursuant to the Investor Rights Agreement, dated as of July 29, 2015, between the Issuer and M&F TTP, as successor in interest to vTv Therapeutics Holdings LLC. Read SEC document |
| July 09, 2019 Filed Jul 9, 2019 16:35 UTC | vTv Therapeutics Inc. VTVT · Entity 6614 | PurchaseClass A common stock | 1,212,121 | $1.65 | $1,999,999.65 |
DisclosureSEC source: 0001140361-19-012655 · form4.xml · nonDerivative · entry 1 PERELMAN RONALD O · CIK 0001186472 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 20,276,593 F1 · ownership.nature: The ROP Revocable Trust dated 1/9/2018 (the "ROP Revocable Trust"), of which Mr. Ronald O. Perelman is the sole trustee and sole beneficiary, is the sole stockholder of MacAndrews & Forbes Incorporated ("M&F Inc."), which is the parent of MFV Holdings One LLC ("MFV") and MacAndrews & Forbes LLC ("M&F LLC"), which is the parent of M&F Group. M&F Group and MFV hold the securities described above. Mr. Perelman, the ROP Revocable Trust, M&F Inc., M&F LLC, M&F Group and MFV may be deemed to be directors by deputization of vTv Therapeutics Inc. (the "Issuer") by virtue of their relationship with Steven M. Cohen and Paul G. Savas, directors of the Issuer, and certain rights of M&F TTP Holdings Two LLC, an indirect subsidiary of M&F Inc. ("M&F TTP"), pursuant to the Investor Rights Agreement, dated as of July 29, 2015, between the Issuer and M&F TTP, as successor in interest to vTv Therapeutics Holdings LLC. Read SEC document |
| June 25, 2019 Filed Jun 26, 2019 08:52 UTC | vTv Therapeutics Inc. VTVT · Entity 6614 | OtherCall Option (right to buy) · Derivative | 1 | $0.00 Strike: $1.65 | $0.00 |
DisclosureSEC source: 0001140361-19-011603 · form4.xml · derivative · entry 2 PERELMAN RONALD O · CIK 0001186472 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1 Underlying: Class A common stock · 1,212,121 shares Expires 2020-03-18 F2 · kind: On March 18, 2019, M&F Group entered into a letter agreement (the "Letter Agreement"), with the Issuer for M&F Group's commitment to purchase, at the Issuer's option, exercisable on demand during a one-year period (the "Investment Period"), the Company's Class A common stock, par value $0.01 per share ("Common Stock") at a per share price of $1.65. The Letter Agreement also permits M&F Group to exercise an option to purchase Common Stock at the same price up to three times during the Investment Period. The aggregate amount of Common Stock that may be purchased by M&F Group is limited to $9.0 million. On June 25, 2019, the Issuer exercised its right to have M&F Group purchase 1,212,121 shares of Common Stock for a total purchase price of $2,000,000 in cash. F2 · balance_after: On March 18, 2019, M&F Group entered into a letter agreement (the "Letter Agreement"), with the Issuer for M&F Group's commitment to purchase, at the Issuer's option, exercisable on demand during a one-year period (the "Investment Period"), the Company's Class A common stock, par value $0.01 per share ("Common Stock") at a per share price of $1.65. The Letter Agreement also permits M&F Group to exercise an option to purchase Common Stock at the same price up to three times during the Investment Period. The aggregate amount of Common Stock that may be purchased by M&F Group is limited to $9.0 million. On June 25, 2019, the Issuer exercised its right to have M&F Group purchase 1,212,121 shares of Common Stock for a total purchase price of $2,000,000 in cash. F1 · ownership.nature: The ROP Revocable Trust dated 1/9/2018 (the "ROP Revocable Trust"), of which Mr. Ronald O. Perelman is the sole trustee and sole beneficiary, is the sole stockholder of MacAndrews & Forbes Incorporated ("M&F Inc."), which is the parent of MFV Holdings One LLC ("MFV") and MacAndrews & Forbes LLC ("M&F LLC"), which is the parent of M&F Group. M&F Group and MFV hold the securities described above. Mr. Perelman, the ROP Revocable Trust, M&F Inc., M&F LLC, M&F Group and MFV may be deemed to be directors by deputization of vTv Therapeutics Inc. (the "Issuer") by virtue of their relationship with Steven M. Cohen and Paul G. Savas, directors of the Issuer, and certain rights of M&F TTP Holdings Two LLC, an indirect subsidiary of M&F Inc. ("M&F TTP"), pursuant to the Investor Rights Agreement, dated as of July 29, 2015, between the Issuer and M&F TTP, as successor in interest to vTv Therapeutics Holdings LLC. Read SEC document |
| June 25, 2019 Filed Jun 26, 2019 08:52 UTC | vTv Therapeutics Inc. VTVT · Entity 6614 | PurchaseClass A common stock | 1,212,121 | $1.65 | $1,999,999.65 |
DisclosureSEC source: 0001140361-19-011603 · form4.xml · nonDerivative · entry 1 PERELMAN RONALD O · CIK 0001186472 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 19,064,472 F1 · ownership.nature: The ROP Revocable Trust dated 1/9/2018 (the "ROP Revocable Trust"), of which Mr. Ronald O. Perelman is the sole trustee and sole beneficiary, is the sole stockholder of MacAndrews & Forbes Incorporated ("M&F Inc."), which is the parent of MFV Holdings One LLC ("MFV") and MacAndrews & Forbes LLC ("M&F LLC"), which is the parent of M&F Group. M&F Group and MFV hold the securities described above. Mr. Perelman, the ROP Revocable Trust, M&F Inc., M&F LLC, M&F Group and MFV may be deemed to be directors by deputization of vTv Therapeutics Inc. (the "Issuer") by virtue of their relationship with Steven M. Cohen and Paul G. Savas, directors of the Issuer, and certain rights of M&F TTP Holdings Two LLC, an indirect subsidiary of M&F Inc. ("M&F TTP"), pursuant to the Investor Rights Agreement, dated as of July 29, 2015, between the Issuer and M&F TTP, as successor in interest to vTv Therapeutics Holdings LLC. Read SEC document |
| June 20, 2019 Filed Jun 24, 2019 10:09 UTC | Light & Wonder, Inc. SGMS · Entity 9758 | PurchaseCommon Stock | 75,000 | $20.21 | $1,515,750.00 |
DisclosureSEC source: 0000950157-19-000737 · form4.xml · nonDerivative · entry 1 PERELMAN RONALD O · CIK 0001186472 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 36,443,768 F1 · price: The transaction was executed in multiple trades at prices ranging from $20.14 to $20.26. The price reported above reflects the weighted average purchase price. Details regarding aggregated purchase transactions will be provided upon request by the Commission staff, the issuer or a security holder of the issuer. F2 · ownership.nature: Mr. Perelman is the beneficiary and trustee of The ROP Revocable Trust dated 1/9/2018 (the "Trust"), which directly holds 88,032 shares of common stock. The Trust is also the sole stockholder of MacAndrews & Forbes Incorporated, which is the sole stockholder, directly or indirectly, of each of SGMS Acquisition Corporation, RLX Holdings Two LLC, SGMS Acquisition Two LLC, SGMS Acquisition Three LLC and MacAndrews & Forbes Group, LLC, which hold the remaining securities described above. Read SEC document |
| June 19, 2019 Filed Jun 19, 2019 22:33 UTC | Light & Wonder, Inc. SGMS · Entity 9758 | PurchaseCommon Stock | 120,000 | $20.29 | $2,434,800.00 |
DisclosureSEC source: 0000950157-19-000730 · form4.xml · nonDerivative · entry 1 PERELMAN RONALD O · CIK 0001186472 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 36,368,768 F1 · price: The transaction was executed in multiple trades at prices ranging from $20.06 to $20.55. The price reported above reflects the weighted average purchase price. Details regarding aggregated purchase transactions will be provided upon request by the Commission staff, the issuer or a security holder of the issuer. F2 · ownership.nature: Mr. Perelman is the beneficiary and trustee of The ROP Revocable Trust dated 1/9/2018 (the "Trust"), which directly holds 88,032 shares of common stock. The Trust is also the sole stockholder of MacAndrews & Forbes Incorporated, which is the sole stockholder, directly or indirectly, of each of SGMS Acquisition Corporation, RLX Holdings Two LLC, SGMS Acquisition Two LLC, SGMS Acquisition Three LLC and MacAndrews & Forbes Group, LLC, which hold the remaining securities described above. Read SEC document |
| June 19, 2019 Filed Jun 21, 2019 21:00 UTC | Light & Wonder, Inc. SGMS · Entity 9758 | Exercise / conversionRestricted Stock Units · Derivative | 1,555 | $0.00 | $0.00 |
DisclosureSEC source: 0000750004-19-000097 · wf-form4_156115084037703.xml · derivative · entry 3 PERELMAN RONALD O · CIK 0001186472 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,110 Underlying: Common Stock · 1,555 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Represents vesting of one-fourth of restricted stock units granted on June 19, 2017. The balance of the award is scheduled to vest in equal installments of 1,555 shares on each of June 19, 2020 and June 19, 2021. Each unit converts into a share of common stock on a one-for-one basis. F2 · derivative.exercise_date: Represents vesting of one-fourth of restricted stock units granted on June 19, 2017. The balance of the award is scheduled to vest in equal installments of 1,555 shares on each of June 19, 2020 and June 19, 2021. Each unit converts into a share of common stock on a one-for-one basis. F2 · derivative.expiration_date: Represents vesting of one-fourth of restricted stock units granted on June 19, 2017. The balance of the award is scheduled to vest in equal installments of 1,555 shares on each of June 19, 2020 and June 19, 2021. Each unit converts into a share of common stock on a one-for-one basis. Read SEC document |
| June 19, 2019 Filed Jun 21, 2019 21:00 UTC | Light & Wonder, Inc. SGMS · Entity 9758 | Exercise / conversionCommon Stock | 1,555 | $0.00 | $0.00 |
DisclosureSEC source: 0000750004-19-000097 · wf-form4_156115084037703.xml · nonDerivative · entry 1 PERELMAN RONALD O · CIK 0001186472 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,074 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 17, 2019 Filed Jun 18, 2019 01:17 UTC | Light & Wonder, Inc. SGMS · Entity 9758 | PurchaseCommon Stock | 110,000 | $19.73 | $2,170,300.00 |
DisclosureSEC source: 0000950157-19-000717 · form4.xml · nonDerivative · entry 1 PERELMAN RONALD O · CIK 0001186472 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 36,248,768 F1 · price: The transaction was executed in multiple trades at prices ranging from $19.41 to $19.85. The price reported above reflects the weighted average purchase price. Details regarding aggregated purchase transactions will be provided upon request by the Commission staff, the issuer or a security holder of the issuer. F2 · ownership.nature: Mr. Perelman is the beneficiary and trustee of The ROP Revocable Trust dated 1/9/2018 (the "Trust"), which directly holds 88,032 shares of common stock. The Trust is also the sole stockholder of MacAndrews & Forbes Incorporated, which is the sole stockholder, directly or indirectly, of each of SGMS Acquisition Corporation, RLX Holdings Two LLC, SGMS Acquisition Two LLC, SGMS Acquisition Three LLC and MacAndrews & Forbes Group, LLC, which hold the remaining securities described above. Read SEC document |
| June 15, 2019 Filed Jun 18, 2019 01:11 UTC | Light & Wonder, Inc. SGMS · Entity 9758 | Exercise / conversionRestricted Stock Units · Derivative | 4,338 | $0.00 | $0.00 |
DisclosureSEC source: 0000950157-19-000716 · form4.xml · derivative · entry 5 PERELMAN RONALD O · CIK 0001186472 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,339 Underlying: Common Stock · 4,338 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Represents vesting of one-fourth of restricted stock units granted on June 15, 2016. The balance of the award is scheduled to vest on June 15, 2020 (4,339 shares). Each unit converts into a share of common stock on a one-for-one basis. F3 · derivative.exercise_date: Represents vesting of one-fourth of restricted stock units granted on June 15, 2016. The balance of the award is scheduled to vest on June 15, 2020 (4,339 shares). Each unit converts into a share of common stock on a one-for-one basis. F3 · derivative.expiration_date: Represents vesting of one-fourth of restricted stock units granted on June 15, 2016. The balance of the award is scheduled to vest on June 15, 2020 (4,339 shares). Each unit converts into a share of common stock on a one-for-one basis. Read SEC document |
| June 15, 2019 Filed Jun 18, 2019 01:11 UTC | Light & Wonder, Inc. SGMS · Entity 9758 | Exercise / conversionCommon Stock | 4,338 | $0.00 | $0.00 |
DisclosureSEC source: 0000950157-19-000716 · form4.xml · nonDerivative · entry 2 PERELMAN RONALD O · CIK 0001186472 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,519 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 13, 2019 Filed Jun 18, 2019 01:11 UTC | Light & Wonder, Inc. SGMS · Entity 9758 | Exercise / conversionRestricted Stock Units · Derivative | 696 | $0.00 | $0.00 |
DisclosureSEC source: 0000950157-19-000716 · form4.xml · derivative · entry 4 PERELMAN RONALD O · CIK 0001186472 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,091 Underlying: Common Stock · 696 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Represents vesting of one-fourth of restricted stock units granted on June 13, 2018. The balance of the award is scheduled to vest in equal installments of 697 shares on each of June 13, 2020, June 13, 2021 and June 13, 2022. Each unit converts into a share of common stock on a one-for-one basis. F2 · derivative.exercise_date: Represents vesting of one-fourth of restricted stock units granted on June 13, 2018. The balance of the award is scheduled to vest in equal installments of 697 shares on each of June 13, 2020, June 13, 2021 and June 13, 2022. Each unit converts into a share of common stock on a one-for-one basis. F2 · derivative.expiration_date: Represents vesting of one-fourth of restricted stock units granted on June 13, 2018. The balance of the award is scheduled to vest in equal installments of 697 shares on each of June 13, 2020, June 13, 2021 and June 13, 2022. Each unit converts into a share of common stock on a one-for-one basis. Read SEC document |
| June 13, 2019 Filed Jun 18, 2019 01:11 UTC | Light & Wonder, Inc. SGMS · Entity 9758 | Exercise / conversionCommon Stock | 696 | $0.00 | $0.00 |
DisclosureSEC source: 0000950157-19-000716 · form4.xml · nonDerivative · entry 1 PERELMAN RONALD O · CIK 0001186472 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,181 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 12, 2019 Filed Jun 12, 2019 20:43 UTC | Light & Wonder, Inc. SGMS · Entity 9758 | GrantRestricted Stock Units · Derivative | 7,710 | $0.00 | $0.00 |
DisclosureSEC source: 0000750004-19-000060 · wf-form4_156037217088390.xml · derivative · entry 4 PERELMAN RONALD O · CIK 0001186472 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,710 Underlying: Common Stock · 7,710 shares Expires not disclosed F3 · derivative.exercise_price: The restricted stock units are scheduled to vest beginning on June 12, 2020 (1,927 shares) and the balance in three installments on June 12, 2021 (1,928 shares), June 12, 2022 (1,927 shares) and June 12, 2023 (1,928 shares). Each unit converts into a share of common stock on a one-for-one basis. F3 · derivative.exercise_date: The restricted stock units are scheduled to vest beginning on June 12, 2020 (1,927 shares) and the balance in three installments on June 12, 2021 (1,928 shares), June 12, 2022 (1,927 shares) and June 12, 2023 (1,928 shares). Each unit converts into a share of common stock on a one-for-one basis. F3 · derivative.expiration_date: The restricted stock units are scheduled to vest beginning on June 12, 2020 (1,927 shares) and the balance in three installments on June 12, 2021 (1,928 shares), June 12, 2022 (1,927 shares) and June 12, 2023 (1,928 shares). Each unit converts into a share of common stock on a one-for-one basis. Read SEC document |
| June 10, 2019 Filed Jun 12, 2019 20:43 UTC | Light & Wonder, Inc. SGMS · Entity 9758 | Exercise / conversionRestricted Stock Units · Derivative | 2,485 | $0.00 | $0.00 |
DisclosureSEC source: 0000750004-19-000060 · wf-form4_156037217088390.xml · derivative · entry 3 PERELMAN RONALD O · CIK 0001186472 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,485 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Represents vesting of one-fourth of restricted stock units granted on June 10, 2015. The award has fully vested. Each unit converted into a share of common stock on a one-for-one basis. F2 · derivative.exercise_date: Represents vesting of one-fourth of restricted stock units granted on June 10, 2015. The award has fully vested. Each unit converted into a share of common stock on a one-for-one basis. F2 · derivative.expiration_date: Represents vesting of one-fourth of restricted stock units granted on June 10, 2015. The award has fully vested. Each unit converted into a share of common stock on a one-for-one basis. Read SEC document |
| June 10, 2019 Filed Jun 12, 2019 20:43 UTC | Light & Wonder, Inc. SGMS · Entity 9758 | Exercise / conversionCommon Stock | 2,485 | $0.00 | $0.00 |
DisclosureSEC source: 0000750004-19-000060 · wf-form4_156037217088390.xml · nonDerivative · entry 1 PERELMAN RONALD O · CIK 0001186472 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,485 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 07, 2019 Filed Jun 7, 2019 19:28 UTC | REVLON INC /DE/ REV · Entity 115224 | PurchaseClass A Common Stock | 20,000 | $23.51 | $470,268.00 |
DisclosureSEC source: 0001209191-19-035673 · doc4.xml · nonDerivative · entry 3 PERELMAN RONALD O · CIK 0001186472 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote 4 Disclosed balance after: 46,223,321 F3 · price: The reported transactions were executed in multiple trades. The purchase price of $23.5134 reported in Column 4 is the weighted average purchase price for the 20,000 shares acquired by the Reporting Person within a range of $23.01 to $23.75 per share. The Reporting Person hereby undertakes to provide to the Staff of the SEC, the Issuer or any security holder of the Issuer, upon request, full information regarding the number of shares acquired at each separate price within the price range noted above. F4 · balance_after: Of the 46,223,321 shares of Class A Common Stock reported herein, (i) 41,676,969 shares of Class A Common Stock are owned by MacAndrews & Forbes Incorporated ("M&F") or its wholly-owned subsidiaries; and (ii) 4,546,352 shares of Class A Common Stock are owned by Perelman Trust Company, LLC, over which M&F exercises voting control. The ROP Revocable Trust dated 1/9/2018, of which Ronald O. Perelman is the sole trustee and beneficiary, is the sole stockholder of M&F. Read SEC document |
| June 05, 2019 Filed Jun 7, 2019 19:28 UTC | REVLON INC /DE/ REV · Entity 115224 | PurchaseClass A Common Stock | 13,228 | $23.37 | $309,144.97 |
DisclosureSEC source: 0001209191-19-035673 · doc4.xml · nonDerivative · entry 2 PERELMAN RONALD O · CIK 0001186472 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote 4 Disclosed balance after: 46,203,321 F2 · price: The reported transactions were executed in multiple trades. The purchase price of $23.3705 reported in Column 4 is the weighted average purchase price for the 13,228 shares acquired by the Reporting Person within a range of $23.28 to $23.49 per share. The Reporting Person hereby undertakes to provide to the Staff of the SEC, the Issuer or any security holder of the Issuer, upon request, full information regarding the number of shares acquired at each separate price within the price range noted above. Read SEC document |
| June 05, 2019 Filed Jun 7, 2019 19:28 UTC | REVLON INC /DE/ REV · Entity 115224 | PurchaseClass A Common Stock | 16,772 | $23.05 | $386,582.86 |
DisclosureSEC source: 0001209191-19-035673 · doc4.xml · nonDerivative · entry 1 PERELMAN RONALD O · CIK 0001186472 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote 4 Disclosed balance after: 46,190,093 F1 · price: The reported transactions were executed in multiple trades. The purchase price of $23.0493 reported in Column 4 is the weighted average purchase price for the 16,772 shares acquired by the Reporting Person within a range of $22.48 to $23.27 per share. The Reporting Person hereby undertakes to provide to the Staff of the SEC, the Issuer or any security holder of the Issuer, upon request, full information regarding the number of shares acquired at each separate price within the price range noted above. Read SEC document |
| June 03, 2019 Filed Jun 3, 2019 17:58 UTC | REVLON INC /DE/ REV · Entity 115224 | PurchaseClass A Common Stock | 30,000 | $21.17 | $635,151.00 |
DisclosureSEC source: 0001209191-19-034035 · doc4.xml · nonDerivative · entry 4 PERELMAN RONALD O · CIK 0001186472 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote 5 Disclosed balance after: 46,173,321 F4 · price: The reported transactions were executed in multiple trades. The purchase price of $21.1717 reported in Column 4 is the weighted average purchase price for the 30,000 shares acquired by the Reporting Person within a range of $20.73 to $21.50 per share. The Reporting Person hereby undertakes to provide to the Staff of the SEC, the Issuer or any security holder of the Issuer, upon request, full information regarding the number of shares acquired at each separate price within the price range noted above. F5 · balance_after: Of the 46,173,321 shares of Class A Common Stock reported herein, (i) 41,626,969 shares of Class A Common Stock are owned by MacAndrews & Forbes Incorporated ("M&F") or its wholly-owned subsidiaries; and (ii) 4,546,352 shares of Class A Common Stock are owned by Perelman Trust Company, LLC, over which M&F exercises voting control. The ROP Revocable Trust dated 1/9/2018, of which Ronald O. Perelman is the sole trustee and beneficiary, is the sole stockholder of M&F. Read SEC document |
| May 31, 2019 Filed Jun 3, 2019 17:58 UTC | REVLON INC /DE/ REV · Entity 115224 | PurchaseClass A Common Stock | 60,000 | $21.25 | $1,274,760.00 |
DisclosureSEC source: 0001209191-19-034035 · doc4.xml · nonDerivative · entry 3 PERELMAN RONALD O · CIK 0001186472 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote 5 Disclosed balance after: 46,143,321 F3 · price: The reported transactions were executed in multiple trades. The purchase price of $21.2460 reported in Column 4 is the weighted average purchase price for the 60,000 shares acquired by the Reporting Person within a range of $20.89 to $21.44 per share. The Reporting Person hereby undertakes to provide to the Staff of the SEC, the Issuer or any security holder of the Issuer, upon request, full information regarding the number of shares acquired at each separate price within the price range noted above. Read SEC document |
| May 30, 2019 Filed Jun 3, 2019 17:58 UTC | REVLON INC /DE/ REV · Entity 115224 | PurchaseClass A Common Stock | 14,257 | $21.87 | $311,863.32 |
DisclosureSEC source: 0001209191-19-034035 · doc4.xml · nonDerivative · entry 2 PERELMAN RONALD O · CIK 0001186472 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote 5 Disclosed balance after: 46,083,321 F2 · price: The reported transactions were executed in multiple trades. The purchase price of $21.8744 reported in Column 4 is the weighted average purchase price for the 14,257 shares acquired by the Reporting Person within a range of $21.76 to $22.04 per share. The Reporting Person hereby undertakes to provide to the Staff of the SEC, the Issuer or any security holder of the Issuer, upon request, full information regarding the number of shares acquired at each separate price within the price range noted above. Read SEC document |
| May 30, 2019 Filed Jun 3, 2019 17:58 UTC | REVLON INC /DE/ REV · Entity 115224 | PurchaseClass A Common Stock | 35,743 | $21.42 | $765,779.48 |
DisclosureSEC source: 0001209191-19-034035 · doc4.xml · nonDerivative · entry 1 PERELMAN RONALD O · CIK 0001186472 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote 5 Disclosed balance after: 46,069,064 F1 · price: The reported transactions were executed in multiple trades. The purchase price of $21.4246 reported in Column 4 is the weighted average purchase price for the 35,743 shares acquired by the Reporting Person within a range of $20.76 to $21.75 per share. The Reporting Person hereby undertakes to provide to the Staff of the SEC, the Issuer or any security holder of the Issuer, upon request, full information regarding the number of shares acquired at each separate price within the price range noted above. Read SEC document |
| May 15, 2019 Filed May 16, 2019 07:54 UTC | vTv Therapeutics Inc. VTVT · Entity 6614 | OtherCall Option (right to buy) · Derivative | 1 | $0.00 Strike: $1.84 | $0.00 |
DisclosureSEC source: 0001140361-19-009238 · form4.xml · derivative · entry 2 PERELMAN RONALD O · CIK 0001186472 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Class A common stock · 1,358,698 shares Expires 2019-12-11 F2 · kind: On December 11, 2018, M&F Group entered into a letter agreement (the "Letter Agreement"), with the Issuer for M&F Group's commitment to purchase, at the Issuer's option, exercisable on demand during a one-year period (the "Investment Period"), the Company's Class A common stock, par value $0.01 per share ("Common Stock") at a per share price of $1.84, which is equal to the closing price of the Common Stock for the trading day preceding the date of the Letter Agreement. The Letter Agreement also permits M&F Group to exercise an option to purchase Common Stock at the same price up to three times during the Investment Period. The aggregate amount of Common Stock that may be purchased by M&F Group is limited to $10.0 million. On May 15, 2019, the Issuer exercised its right to have M&F Group purchase the final 1,358,698 shares of Common Stock for a total purchase price of $2,500,000 in cash. F2 · balance_after: On December 11, 2018, M&F Group entered into a letter agreement (the "Letter Agreement"), with the Issuer for M&F Group's commitment to purchase, at the Issuer's option, exercisable on demand during a one-year period (the "Investment Period"), the Company's Class A common stock, par value $0.01 per share ("Common Stock") at a per share price of $1.84, which is equal to the closing price of the Common Stock for the trading day preceding the date of the Letter Agreement. The Letter Agreement also permits M&F Group to exercise an option to purchase Common Stock at the same price up to three times during the Investment Period. The aggregate amount of Common Stock that may be purchased by M&F Group is limited to $10.0 million. On May 15, 2019, the Issuer exercised its right to have M&F Group purchase the final 1,358,698 shares of Common Stock for a total purchase price of $2,500,000 in cash. F1 · ownership.nature: The ROP Revocable Trust dated 1/9/2018 (the "ROP Revocable Trust"), of which Mr. Ronald O. Perelman is the sole trustee and sole beneficiary, is the sole stockholder of MacAndrews & Forbes Incorporated ("M&F Inc."), which is the parent of MFV Holdings One LLC ("MFV") and MacAndrews & Forbes LLC ("M&F LLC"), which is the parent of M&F Group. M&F Group and MFV hold the securities described above. Mr. Perelman, the ROP Revocable Trust, M&F Inc., M&F LLC, M&F Group and MFV may be deemed to be directors by deputization of vTv Therapeutics Inc. (the "Issuer") by virtue of their relationship with Steven M. Cohen and Paul G. Savas, directors of the Issuer, and certain rights of M&F TTP Holdings Two LLC, an indirect subsidiary of M&F Inc. ("M&F TTP"), pursuant to the Investor Rights Agreement, dated as of July 29, 2015, between the Issuer and M&F TTP, as successor in interest to vTv Therapeutics Holdings LLC. Read SEC document |
| May 15, 2019 Filed May 16, 2019 07:54 UTC | vTv Therapeutics Inc. VTVT · Entity 6614 | PurchaseClass A common stock | 1,358,698 | $1.84 | $2,500,004.32 |
DisclosureSEC source: 0001140361-19-009238 · form4.xml · nonDerivative · entry 1 PERELMAN RONALD O · CIK 0001186472 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 17,852,351 F1 · ownership.nature: The ROP Revocable Trust dated 1/9/2018 (the "ROP Revocable Trust"), of which Mr. Ronald O. Perelman is the sole trustee and sole beneficiary, is the sole stockholder of MacAndrews & Forbes Incorporated ("M&F Inc."), which is the parent of MFV Holdings One LLC ("MFV") and MacAndrews & Forbes LLC ("M&F LLC"), which is the parent of M&F Group. M&F Group and MFV hold the securities described above. Mr. Perelman, the ROP Revocable Trust, M&F Inc., M&F LLC, M&F Group and MFV may be deemed to be directors by deputization of vTv Therapeutics Inc. (the "Issuer") by virtue of their relationship with Steven M. Cohen and Paul G. Savas, directors of the Issuer, and certain rights of M&F TTP Holdings Two LLC, an indirect subsidiary of M&F Inc. ("M&F TTP"), pursuant to the Investor Rights Agreement, dated as of July 29, 2015, between the Issuer and M&F TTP, as successor in interest to vTv Therapeutics Holdings LLC. Read SEC document |
| April 05, 2019 Filed Apr 5, 2019 17:08 UTC | REVLON INC /DE/ REV · Entity 115224 | PurchaseClass A Common Stock | 25,000 | $21.28 | $532,012.50 |
DisclosureSEC source: 0001209191-19-023841 · doc4.xml · nonDerivative · entry 3 PERELMAN RONALD O · CIK 0001186472 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote 4 Disclosed balance after: 46,033,321 F3 · price: The reported transactions were executed in multiple trades. The purchase price of $21.2805 reported in Column 4 is the weighted average purchase price for the 25,000 shares acquired by the Reporting Person within a range of $20.72 to $21.59 per share. The Reporting Person hereby undertakes to provide to the Staff of the SEC, the Issuer or any security holder of the Issuer, upon request, full information regarding the number of shares acquired at each separate price within the price range noted above. F4 · balance_after: Of the 46,033,321 shares of Class A Common Stock reported herein, (i) 41,486,969 shares of Class A Common Stock are owned by MacAndrews & Forbes Incorporated ("M&F") or its wholly-owned subsidiaries; and (ii) 4,546,352 shares of Class A Common Stock are owned by Perelman Trust Company, LLC, over which M&F exercises voting control. The ROP Revocable Trust dated 1/9/2018, of which Ronald O. Perelman is the sole trustee and beneficiary, is the sole stockholder of M&F. Read SEC document |
| April 04, 2019 Filed Apr 5, 2019 17:08 UTC | REVLON INC /DE/ REV · Entity 115224 | PurchaseClass A Common Stock | 20,000 | $21.03 | $420,542.00 |
DisclosureSEC source: 0001209191-19-023841 · doc4.xml · nonDerivative · entry 2 PERELMAN RONALD O · CIK 0001186472 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote 4 Disclosed balance after: 46,008,321 F2 · price: The reported transactions were executed in multiple trades. The purchase price of $21.0271 reported in Column 4 is the weighted average purchase price for the 20,000 shares acquired by the Reporting Person within a range of $20.60 to $21.20 per share. The Reporting Person hereby undertakes to provide to the Staff of the SEC, the Issuer or any security holder of the Issuer, upon request, full information regarding the number of shares acquired at each separate price within the price range noted above. Read SEC document |
| April 03, 2019 Filed Apr 5, 2019 17:08 UTC | REVLON INC /DE/ REV · Entity 115224 | PurchaseClass A Common Stock | 20,000 | $20.96 | $419,110.00 |
DisclosureSEC source: 0001209191-19-023841 · doc4.xml · nonDerivative · entry 1 PERELMAN RONALD O · CIK 0001186472 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote 4 Disclosed balance after: 45,988,321 F1 · price: The reported transactions were executed in multiple trades. The purchase price of $20.9555 reported in Column 4 is the weighted average purchase price for the 20,000 shares acquired by the Reporting Person within a range of $20.65 to $21.115 per share. The Reporting Person hereby undertakes to provide to the Staff of the SEC, the Issuer or any security holder of the Issuer, upon request, full information regarding the number of shares acquired at each separate price within the price range noted above. Read SEC document |
| April 02, 2019 Filed Apr 2, 2019 19:06 UTC | REVLON INC /DE/ REV · Entity 115224 | PurchaseClass A Common Stock | 21,762 | $20.55 | $447,182.99 |
DisclosureSEC source: 0001209191-19-022747 · doc4.xml · nonDerivative · entry 4 PERELMAN RONALD O · CIK 0001186472 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote 5 Disclosed balance after: 45,968,321 F4 · price: The reported transactions were executed in multiple trades. The purchase price of $20.5488 reported in Column 4 is the weighted average purchase price for the 21,762 shares acquired by the Reporting Person within a range of $20.45 to $20.75 per share. The Reporting Person hereby undertakes to provide to the Staff of the SEC, the Issuer or any security holder of the Issuer, upon request, full information regarding the number of shares acquired at each separate price within the price range noted above. F5 · balance_after: Of the 45,968,321 shares of Class A Common Stock reported herein, (i) 41,421,969 shares of Class A Common Stock are owned by MacAndrews & Forbes Incorporated ("M&F") or its wholly-owned subsidiaries; and (ii) 4,546,352 shares of Class A Common Stock are owned by Perelman Trust Company, LLC, over which M&F exercises voting control. The ROP Revocable Trust dated 1/9/2018, of which Ronald O. Perelman is the sole trustee and beneficiary, is the sole stockholder of M&F. Read SEC document |
| April 02, 2019 Filed Apr 2, 2019 19:06 UTC | REVLON INC /DE/ REV · Entity 115224 | PurchaseClass A Common Stock | 23,238 | $20.27 | $471,038.91 |
DisclosureSEC source: 0001209191-19-022747 · doc4.xml · nonDerivative · entry 3 PERELMAN RONALD O · CIK 0001186472 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote 5 Disclosed balance after: 45,946,559 F3 · price: The reported transactions were executed in multiple trades. The purchase price of $20.2702 reported in Column 4 is the weighted average purchase price for the 23,238 shares acquired by the Reporting Person within a range of $19.73 to $20.44 per share. The Reporting Person hereby undertakes to provide to the Staff of the SEC, the Issuer or any security holder of the Issuer, upon request, full information regarding the number of shares acquired at each separate price within the price range noted above. Read SEC document |
| April 01, 2019 Filed Apr 2, 2019 19:06 UTC | REVLON INC /DE/ REV · Entity 115224 | PurchaseClass A Common Stock | 50,090 | $20.24 | $1,013,576.16 |
DisclosureSEC source: 0001209191-19-022747 · doc4.xml · nonDerivative · entry 2 PERELMAN RONALD O · CIK 0001186472 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote 5 Disclosed balance after: 45,923,321 F2 · price: The reported transactions were executed in multiple trades. The purchase price of $20.2351 reported in Column 4 is the weighted average purchase price for the 50,090 shares acquired by the Reporting Person within a range of $20.05 to $20.47 per share. The Reporting Person hereby undertakes to provide to the Staff of the SEC, the Issuer or any security holder of the Issuer, upon request, full information regarding the number of shares acquired at each separate price within the price range noted above. Read SEC document |
| April 01, 2019 Filed Apr 2, 2019 19:06 UTC | REVLON INC /DE/ REV · Entity 115224 | PurchaseClass A Common Stock | 19,910 | $19.74 | $393,035.35 |
DisclosureSEC source: 0001209191-19-022747 · doc4.xml · nonDerivative · entry 1 PERELMAN RONALD O · CIK 0001186472 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote 5 Disclosed balance after: 45,873,231 F1 · price: The reported transactions were executed in multiple trades. The purchase price of $19.7406 reported in Column 4 is the weighted average purchase price for the 19,910 shares acquired by the Reporting Person within a range of $19.05 to $20.04 per share. The Reporting Person hereby undertakes to provide to the Staff of the SEC, the Issuer or any security holder of the Issuer, upon request, full information regarding the number of shares acquired at each separate price within the price range noted above. Read SEC document |
| March 26, 2019 Filed Mar 26, 2019 19:30 UTC | REVLON INC /DE/ REV · Entity 115224 | PurchaseClass A Common Stock | 2,800 | $21.71 | $60,779.60 |
DisclosureSEC source: 0001209191-19-021372 · doc4.xml · nonDerivative · entry 2 PERELMAN RONALD O · CIK 0001186472 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote 3 Disclosed balance after: 45,853,321 F2 · price: The reported transactions were executed in multiple trades. The purchase price of $21.7070 reported in Column 4 is the weighted average purchase price for the 2,800 shares acquired by the Reporting Person within a range of $21.64 to $21.77 per share. The Reporting Person hereby undertakes to provide to the Staff of the SEC, the Issuer or any security holder of the Issuer, upon request, full information regarding the number of shares acquired at each separate price within the price range noted above. F3 · balance_after: Of the 45,853,321 shares of Class A Common Stock reported herein, (i) 41,306,969 shares of Class A Common Stock are owned by MacAndrews & Forbes Incorporated ("M&F") or its wholly-owned subsidiaries; and (ii) 4,546,352 shares of Class A Common Stock are owned by Perelman Trust Company, LLC, over which M&F exercises voting control. The ROP Revocable Trust dated 1/9/2018, of which Ronald O. Perelman is the sole trustee and beneficiary, is the sole stockholder of M&F. Read SEC document |
| March 26, 2019 Filed Mar 26, 2019 19:30 UTC | REVLON INC /DE/ REV · Entity 115224 | PurchaseClass A Common Stock | 32,200 | $21.37 | $688,149.42 |
DisclosureSEC source: 0001209191-19-021372 · doc4.xml · nonDerivative · entry 1 PERELMAN RONALD O · CIK 0001186472 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote 3 Disclosed balance after: 45,850,521 F1 · price: The reported transactions were executed in multiple trades. The purchase price of $21.3711 reported in Column 4 is the weighted average purchase price for the 32,200 shares acquired by the Reporting Person within a range of $20.64 to $21.63 per share. The Reporting Person hereby undertakes to provide to the Staff of the SEC, the Issuer or any security holder of the Issuer, upon request, full information regarding the number of shares acquired at each separate price within the price range noted above. Read SEC document |
| March 25, 2019 Filed Mar 25, 2019 18:42 UTC | REVLON INC /DE/ REV · Entity 115224 | PurchaseClass A Common Stock | 40,000 | $20.53 | $821,016.00 |
DisclosureSEC source: 0001209191-19-021232 · doc4.xml · nonDerivative · entry 3 PERELMAN RONALD O · CIK 0001186472 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote 4 Disclosed balance after: 45,818,321 F3 · price: The reported transactions were executed in multiple trades. The purchase price of $20.5254 reported in Column 4 is the weighted average purchase price for the 40,000 shares acquired by the Reporting Person within a range of $20.08 to $20.95 per share. The Reporting Person hereby undertakes to provide to the Staff of the SEC, the Issuer or any security holder of the Issuer, upon request, full information regarding the number of shares acquired at each separate price within the price range noted above. F4 · balance_after: Of the 45,818,321 shares of Class A Common Stock reported herein, (i) 41,271,969 shares of Class A Common Stock are owned by MacAndrews & Forbes Incorporated ("M&F") or its wholly-owned subsidiaries; and (ii) 4,546,352 shares of Class A Common Stock are owned by Perelman Trust Company, LLC, over which M&F exercises voting control. The ROP Revocable Trust dated 1/9/2018, of which Ronald O. Perelman is the sole trustee and beneficiary, is the sole stockholder of M&F. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.